A future rheumatologist attending the #ACR22 Plenary session virtually to keep up with the latest information. ⁦@RheumNow⁩ https://t.co/ttYr4iwTB8

Barroso-García et al. ADA vs IFX vs TCZ in severe ocular Behcets with refractory cystoid macular edema. Remission 76% (ADA), 60% (IFX), 67% (TCZ). @RheumNow #ACR22 Abstr#1564 https://t.co/pRVgIdGAGS https://t.co/gOb5wQ9pHv

• Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involveme…

Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 💊Phase 3, randomized, placebo-controlled study 💉Biologic naive patients ✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi) 📍benefits sustained to week 52 🛑No new safety signals

Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful. @RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM

PJP occurs in pts w/ AAV who undergo treatment w/ CYC or RTX, but PJP PPX assoc'd w/ inc incidence of medication-related adverse events. Abs 1081 #ACR22 @RheumNow https://t.co/7vMgx7eMAP https://t.co/bhKPtJBMAO

• Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis I…

DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64

• Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh…

#ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg

From my colleague @aili_yoyo. Mimics of vasculitis picked up on imaging. "Isolated abdominal vasculitis" is a surprisingly common consult. Can be tricky sometimes. @RheumNow #ACR22 #mimics https://t.co/QfeaTHHzdA

Rheumatic Masqueraders: Mimics of Rheumatic Diseases Mimics of Vasculitis by - Demographics - Vascular Distribution -**Imaging - Labs - Clinical Presentation #ACR22 @RheumNow https://t.co/o0pZoiMqI2

FIND-RA study from Belgium attempts to quantify ILD in early RA. Previously wide ranging estimates 5-20%. They found ILD in 13%. Awaiting full data on ILD severity and progression. @RheumNow ABST1393 #ACR22 https://t.co/ol4iCTkbn9 https://t.co/RLG1ur21dj

• Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA …

Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 years; after trial end, effect dissipated and no longer overall significant. No change in borderline effect of 1000 mg/day omega3. @RheumNow #ACR22 Abstr#1200 https://t.co/lebdzWIO4n https://t.co/HKbHwLihrI

• Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmun…

Fascinating Abs 0653 #ACR22 In vitro models show JAKis counteract celluar cytotoxicity of HCQ in a human retinal pigment epithelial cell line and podocytes. Possible new way to dec. retinopathy/nephropathy? @RheumNow https://t.co/5NtLoDzjKG https://t.co/GG2R03xAes

• JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro - AC…

BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV

• Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shift…

What delays diagnosis of AS? #ACR22 @RheumNow Abstract #0328 Diagnosed faster if: 👨‍🦳Older age at back pain onset 🧬HLA-B27+ ✋🦶peripheral arthritis 📍Higher socioeconomic vulnerability had diagnostic delay 👁 uveitis more common in patients with > 4 years dx delay